Compare Gilead Sciences, Inc. (GILD) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Teucrium Wheat Fund — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Teucrium Wheat Fund trades at $24.8 (market cap $273.67M). The key difference: Gilead Sciences, Inc. is far larger — about 666.5× Teucrium Wheat Fund's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Teucrium Wheat Fund for 40 Days on average.
| GILD | WEAT | |
|---|---|---|
Market Cap | $182.40B | $273.67M |
Volume | 4,469,821 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $28.00 |
52-Week Low | $116.74 | $19.88 |
Typical Hold Time | 111 Days | 40 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
WEAT trades at $24.9, down 2.31% over the past day amid a bearish technical signal from moving averages. The stock's technical indicators show neutral oscillators but selling pressure from the ADX. Recent news highlights WEAT's strong performance earlier in the year, with a 25% year-to-date gain as of July 2026, though inflation concerns persist as a market-wide theme.
The outlook for WEAT is cautious due to bearish technical momentum and macroeconomic headwinds from inflation. Investment opportunity exists if the stock holds key support levels, but risks include continued selling pressure and sensitivity to broader economic conditions. Investors should weigh technical weakness against the fund's earlier 2026 gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
